Sp626

PRESENTATION OF CLINICAL PRACTICE (CP) SECTION RESEARCH MENTOR AWARD: ROBERT (ROCKY) E. SCHOEN, MD, MPH

Date
May 19, 2024
Explore related products in the following collection:

Presenters

Speaker Image for Gary Falk
Unversity of Pennsylvania
Speaker Image for Aasma Shaukat
New York University

Tracks

Related Products

Thumbnail for THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT’S ESOPHAGUS
THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT’S ESOPHAGUS
INTRODUCTION: The goal of Barrett’s esophagus (BE) surveillance is to detect dysplasia and esophageal adenocarcinoma (EAC) at early, treatable stages…
Thumbnail for Reducing CRC Incidence Through Screening and Surveillance
Reducing CRC Incidence Through Screening and Surveillance
SOCIETY: AGA CRC screening and surveillance
Thumbnail for A COMPREHENSIVE ANALYSIS OF COLORECTAL CANCER INCIDENCE IN THE UNITED STATES: A POPULATION-BASED TIME-TREND ANALYSIS OVER 20 YEARS
A COMPREHENSIVE ANALYSIS OF COLORECTAL CANCER INCIDENCE IN THE UNITED STATES: A POPULATION-BASED TIME-TREND ANALYSIS OVER 20 YEARS
Introduction: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States (US). Previous reports have shown significant changes in the epidemiology of CRC…
Thumbnail for FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…